Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | UBE2M | P61081 | 1/20 | 0.44 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5366253 | 0.86 | OPRM1 (0.50) | OPRM1CHRM2CHRM3HSD11B1SIGMAR1 | |
| SCHEMBL28696384 | 0.86 | HSD11B1 (0.50) | OPRM1HSD11B1 | |
| SCHEMBL22391801 | 0.84 | HSD11B1 (0.51) | HSD11B1HTR2A | |
| SCHEMBL16054269 | 0.83 | OPRM1 (0.59) | OPRM1CHRM2CHRM3HSD11B1SIGMAR1 | |
| SCHEMBL14410252 | 0.83 | HSD11B1 (0.43) | HSD11B1UBE2MDCUN1D1HTR2A | |
| SCHEMBL5378020 | 0.82 | OPRM1 (0.48) | OPRM1CHRM2CHRM3HSD11B1SIGMAR1 | |
| SCHEMBL14417237 | 0.80 | SLC6A4 (0.50) | CHRM3KCNH2 | |
| Hydrochloric Acid SCHEMBL8480640 | 0.80 | OPRM1 (0.52) | OPRM1CHRM2CHRM3HSD11B1SIGMAR1 | |
| SCHEMBL28741984 | 0.80 | OPRM1 (0.53) | OPRM1CHRM2CHRM3SIGMAR1KCNH2 | |
| SCHEMBL8189152 | 0.80 | CCR5 (0.58) | OPRM1CHRM2CHRM3SIGMAR1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7230001-B1 | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-12 | — | — | US | disclosed |
| WO-2007053145-A1 | HALOPERIDOL ANALOGS | FLORIDA A & M UNIVERSITY (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | ARRB1, NPY1R, ADRB3 | OPRM1 18/4885CHRM2 112/4885CHRM3 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.